Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

April 15, 2008

Alimta (Lilly): Approved as First Line Agent in Europe for Non Squamous Cell Lung Ca!!!

Analysis of: ALIMTA(R) (pemetrexed for injection) Receives European Approval for Histologically-Based Use in First-Line Treatment of Most Common Lung Cancer | www.pipelinereview.com
This analysis is solely the work of the author. It has not been edited or endorsed by GLG.
Analysis By:
Kenneth Algazy, MD, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CCKenneth Algazy, MD 
Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CC
Implications: Alimta will be used first line with Cis Platin as a primary therapy for non squamous non small cell lung cancer (NSCLCA)

Analysis: In my mind this is major, and it is only a matter of time until it is approved in the US for first line use. It is a non toxic, effective agent that can be repeated monthly for years. In the US it will be modified by the practitioners to be given with carboplatin. I see a bright future!
The only ones who will be adversely effected will be Taxol (generic) and Taxotere (Sanofi) who will have to share the first line market.

Other Analyses of the Same Source Article:
Non small cell lung cancer has little to be excited about
April 16, 2008, Author: Donald Fleming, MD, Division Head of Hematology and Oncology, Davis Health System, Inc.

Report a Concern

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics